Reconstitution and Characterization of BCL-2 Family Proteins in Lipid Bilayer Nanodiscs.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2019
Historique:
entrez: 12 12 2018
pubmed: 12 12 2018
medline: 1 6 2019
Statut: ppublish

Résumé

The BCL-2 family proteins are key regulators of programmed cell death or apoptosis, and represent important targets for the development of anticancer drugs. Because their functions are intimately connected with intracellular membranes, it is important to perform structural and activity studies in precisely characterized samples that include phospholipids and capture the features of the native physiological environment as closely as possible. NMR studies and activity assays based on lipid bilayer nanodiscs are ideally suited for this purpose: they enable the conformations and interactions of these proteins to be probed at atomic resolution in their membrane-associated states. Here we describe detailed protocols for generating the protein components and the reconstituted nanodisc samples suitable for NMR studies and functional assays. The protocols focus on the BCL-2 family protein BCL-XL, a dominant inhibitor of programmed cell death and a major anticancer drug target. The protocols are relatively straightforward. Provided care is taken to ensure protein integrity and sample homogeneity, BCL-XL can be readily reconstituted in nanodiscs, with its hydrophobic C-terminal tail anchored through the nanodisc lipid bilayer, and its folded N-terminal head and ligand binding pocket exposed to the aqueous solution. We anticipate that BCL-2 samples prepared with these protocols will advance structural and mechanistic studies for this important protein family.

Identifiants

pubmed: 30536010
doi: 10.1007/978-1-4939-8861-7_16
pmc: PMC6599400
mid: NIHMS1031481
doi:

Substances chimiques

Antineoplastic Agents 0
BCL2 protein, human 0
Lipid Bilayers 0
Membrane Proteins 0
Phospholipids 0
Proto-Oncogene Proteins c-bcl-2 0
bcl-X Protein 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

233-246

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM118186
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA030199
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM100265
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA179087
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB002031
Pays : United States

Références

Q Rev Biophys. 2000 Feb;33(1):29-65
pubmed: 11075388
Methods Enzymol. 2001;339:174-203
pubmed: 11462811
Magn Reson Chem. 2004 Feb;42(2):172-9
pubmed: 14745797
J Am Chem Soc. 2004 Mar 24;126(11):3477-87
pubmed: 15025475
Nature. 2005 Jun 2;435(7042):677-81
pubmed: 15902208
Biochemistry. 2006 Feb 21;45(7):2250-6
pubmed: 16475813
Biochemistry. 2007 Feb 27;46(8):2059-69
pubmed: 17263563
Methods Enzymol. 2009;464:211-31
pubmed: 19903557
Q Rev Biophys. 1990 May;23(2):97-131
pubmed: 2188281
J Biomol NMR. 1994 Sep;4(5):603-14
pubmed: 22911360
Cell Death Differ. 2013 Feb;20(2):333-42
pubmed: 23079612
J Am Chem Soc. 2013 Feb 6;135(5):1919-25
pubmed: 23294159
Nat Chem Biol. 2013 Jun;9(6):390-7
pubmed: 23603658
Cell Death Dis. 2013 Nov 07;4:e909
pubmed: 24201808
J Mol Biol. 2015 Jul 3;427(13):2262-70
pubmed: 25731750
Protein Expr Purif. 2016 Jun;122:56-63
pubmed: 26923059
Biol Chem. 2016 Dec 1;397(12):1335-1354
pubmed: 27451995
Development. 1994 Oct;120(10):3033-42
pubmed: 7607090
J Immunol. 1994 Nov 15;153(10):4388-98
pubmed: 7963517
Cell. 1993 Aug 27;74(4):597-608
pubmed: 8358789
J Biomol NMR. 1995 Nov;6(3):277-93
pubmed: 8520220
Brain Res. 1996 Mar 18;712(2):281-6
pubmed: 8814903
Science. 1997 Feb 14;275(5302):983-6
pubmed: 9020082
J Cell Biol. 1997 Dec 1;139(5):1281-92
pubmed: 9382873
Curr Opin Chem Biol. 1998 Oct;2(5):564-70
pubmed: 9818180

Auteurs

Yong Yao (Y)

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Francesca M Marassi (FM)

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. fmarassi@sbp.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH